TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer
Clinicaltrials.gov identifier:
NCT02975934
Treatment
Study Contact Information:
Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email
The study is open and recruiting at sites in CA, FL, GA, HI, MD, NE, NV, NJ, NY, NC, OH, TN, TX, VA.
A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)
About the Study
The purpose of Triton3 is to determine how patients with castration-resistant cancer, and an inherited gene mutation or tumor genetic deficiency respond to treatment with the rucaparib () compared to treatment with physician's choice of acetate, , or docetaxel. NOTE: This study is no longer enrolling patients.
Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email
NOTE: This study is no longer enrolling patients.
NOTE: This study is no longer enrolling patients.